L., & Nichols, W
It belongs to a novel class of agents known as triple receptor agonists , meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1) which reduces appetite and slows gastric emptying [7] [8] GIP (glucose-dependent insulinotropic polypeptide) which is hypothesised to enhance insulin secretion and may play a role in fat metabolism, though the precise contribution remains under investigation Glucagon receptor which is thought to increase energy expenditure and promote hepatic fat breakdown, though these mechanisms are still being characterised in human studies [9] [10] This triple mechanism distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist), and is thought to produce more pronounced effects on body weight

Because they contain the same active ingredient, both these medications share many benefits, such as reducing insulin resistance, lowering inflammation, and potentially decreasing the risk of complications related to obesity and cardiovascular disease 1 , 2 , 5
Apply to wet skin in the shower, massage using circular motions
June 12, 2026 Health ConditionsSee all Health Conditions (64) New UTI Pill Utebzi (Tebipenem): Dosing, Side Effects & How to Save on the First Oral Carbapenem Utebzi is the first FDA-approved oral carbapenem for complicated urinary tract infections
A 2024 review of over 14,000 participants found the actual incidence of thyroid cancer with semaglutide to be less than 1%, suggesting no clear increased risk